HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stada Says Lemocin’s OTC Status 'Vindicated' By German Switch Committee Decision

Executive Summary

Stada's Lemocin cough lozenges survive a German reverse-switch threat, as does first generation anti-histamine dimenhydrinate, pointing to possible good news for the company's other major German OTC brand, Hoggar Night (doxylamine), which is also having its OTC status re-examined by the country's Expert Committee on Prescription.

You may also be interested in...



Rx-To-OTC Switch Of Low-Cost Smoking Cessation Drug Cystine Rejected By German Committee

Low-cost smoking cessation alternaitve cystine and azelastine-fluticasone combination nasal spray Rx-to-OTC switch applications were rejected by Germany's independent Expert Committee on Prescription at its latest meeting. Olopatadine for ophthalmic use and oral bilastine at 10mg strength were, however, given the green light. 

Alternative Smoking Cessation Drug Cytisine On 2023 German Switch Committee Agenda

Low-cost alternative smoking cessation drug cytisine is under consideration by Germany's independent switch committee in January, alongside azelastine and fluticasone propionate in combination for intranasal use, olopatadine for ophthalmic use and bilastine (10mg) for oral use.

Stada Wins Battle To Keep Hoggar Night Sleep Aid OTC In Germany

Stada has won a two year battle to keep its Hoggar Night sleep aid (doxylamine) available OTC for German adults aged 65 and older.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel